Therapeutic Effects of Metformin on Central Nervous System Diseases: A Focus on Protection of Neurovascular Unit.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and pre-clinical/clinical literature without systematic review methodology
PubMed 39375240 · doi:10.1007/s11095-024-03777-0
What was done
This narrative review synthesized literature on the therapeutic effects of metformin on the neurovascular unit across retinal conditions (diabetic retinopathy, retinitis pigmentosa) and cerebral disorders (ischemic stroke, Alzheimer's disease).
What was found
The abstract reports no numerical data, effect sizes, or trial counts. It qualitatively notes that metformin crosses the blood-brain barrier and exerts protective effects across multiple neurovascular cell types (photoreceptors, Müller cells, pericytes, astrocytes, microglia, and vascular endothelial cells), primarily by maintaining blood-brain barrier integrity and regulating inflammatory responses.
Why it matters
It highlights shared cellular mechanisms across retinal and brain pathologies where an accessible metabolic drug may offer neurovascular protection.
Limits
The review provides narrative synthesis without systematic search criteria or quantitative data. Optimal clinical dosing, therapeutic timing, treatment duration, human clinical efficacy, and side-effect profiles remain unvalidated.
Cited by
- supports Metformin crosses the blood-brain barrier, supports the TCA cycle in mitochondria, and reduces inflammatory cytokines such as TNF-alpha and interleukin-6 in studies.